Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat(Hospital Clínic de Barcelona), Enriqueta Felip(Institut Català d'Ornitologia), Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari), Lydia Gaba(Hospital Clínic de Barcelona), S. Cedrés(Vall d'Hebron Hospital Universitari), Iván Victoria(Hospital Clínic de Barcelona), Laura Comerma(Hospital Del Mar), Alejandro Navarro(Vall d'Hebron Hospital Universitari), Núria Viñolas(Hospital Clínic de Barcelona), Núria Pardo(Vall d'Hebron Hospital Universitari), Tomás Pascual(Breast Cancer Research Foundation), Joel S. Parker(University of North Carolina at Chapel Hill), Patricia Galván(Vall d'Hebron Institute of Oncology), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ana Vivancos(Vall d'Hebron Institute of Oncology), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Noemı́ Reguart(Hospital Clínic de Barcelona), Llúcia Alós(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Cheng Fan(University of North Carolina at Chapel Hill), Ana Arance(Hospital Clínic de Barcelona)
Cited by 480
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k